Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET
Company Participants
Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy
Mike Exton - Chief Executive Officer and Director
Scott Coiante - Senior Vice President and Chief Financial Officer
Craig Granowitz - Senior Vice President and Chief Medical Officer
Conference Call Participants
Andrew Tsai - Jefferies
Roanna Ruiz - Leerink Partners
Yasmeen Rahimi - Piper Sandler
Yigal Nochomovitz - Citigroup
Lander Gorrono - H.C. Wainwright
Operator
Welcome to the Lexicon Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, May 13, 2025. I will now turn the call over to Lisa DeFrancesco, SVP, Investor Relations and Corporate Communications for Lexicon. Please go ahead, Lisa.
Lisa DeFrancesco
Thank you, Sanan. Good afternoon and welcome to the Lexicon Pharmaceuticals first quarter 2025 financial results conference Call. Joining me today are Dr. Mike Exton, Lexicon's Chief Executive Officer and Director; and Scott Coiante, Senior Vice President and Chief Financial Officer; Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer, will also join us for Q&A.
Earlier this afternoon, Lexicon issued a press release announcing our financial results for the first quarter of 2025, which are available on our website at www.lexiconpharma.com and through our SEC filing. A webcast of this call, along with a slide presentation, is also available on our website. During this call, we will review the information provided in the release, provide a corporate update, and then use the remainder of our time to answer your questions.
Before we begin, let me remind you that we will be making forward-looking statements, including statements related to
- Read more current LXRX analysis and news
- View all earnings call transcripts